vs
Side-by-side financial comparison of Federal Realty Investment Trust (FRT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $336.0M, roughly 1.9× Federal Realty Investment Trust). Federal Realty Investment Trust runs the higher net margin — 38.6% vs 34.4%, a 4.2% gap on every dollar of revenue. On growth, Federal Realty Investment Trust posted the faster year-over-year revenue change (8.7% vs 4.8%). Over the past eight quarters, Federal Realty Investment Trust's revenue compounded faster (6.5% CAGR vs 4.6%).
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
FRT vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $336.0M | $622.0M |
| Net Profit | $129.7M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 53.8% | 62.4% |
| Net Margin | 38.6% | 34.4% |
| Revenue YoY | 8.7% | 4.8% |
| Net Profit YoY | 103.5% | 2.9% |
| EPS (diluted) | $1.49 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.0M | — | ||
| Q4 25 | $336.0M | $622.0M | ||
| Q3 25 | $322.3M | $609.3M | ||
| Q2 25 | $311.5M | $578.7M | ||
| Q1 25 | $309.2M | $568.2M | ||
| Q4 24 | $311.4M | $593.6M | ||
| Q3 24 | $303.6M | $564.7M | ||
| Q2 24 | $296.1M | $537.3M |
| Q1 26 | $129.7M | — | ||
| Q4 25 | $129.7M | $214.2M | ||
| Q3 25 | $61.6M | $288.2M | ||
| Q2 25 | $155.9M | $30.2M | ||
| Q1 25 | $63.8M | $238.3M | ||
| Q4 24 | $65.5M | $208.2M | ||
| Q3 24 | $61.0M | $544.0M | ||
| Q2 24 | $112.0M | $102.0M |
| Q1 26 | 53.8% | — | ||
| Q4 25 | 53.8% | 62.4% | ||
| Q3 25 | 34.3% | 70.1% | ||
| Q2 25 | 65.1% | 36.3% | ||
| Q1 25 | 35.0% | 94.0% | ||
| Q4 24 | 35.1% | 60.9% | ||
| Q3 24 | 34.9% | — | ||
| Q2 24 | 53.0% | 50.2% |
| Q1 26 | 38.6% | — | ||
| Q4 25 | 38.6% | 34.4% | ||
| Q3 25 | 19.1% | 47.3% | ||
| Q2 25 | 50.0% | 5.2% | ||
| Q1 25 | 20.6% | 41.9% | ||
| Q4 24 | 21.0% | 35.1% | ||
| Q3 24 | 20.1% | 96.3% | ||
| Q2 24 | 37.8% | 19.0% |
| Q1 26 | $1.49 | — | ||
| Q4 25 | $1.49 | $0.49 | ||
| Q3 25 | $0.69 | $0.67 | ||
| Q2 25 | $1.78 | $0.07 | ||
| Q1 25 | $0.72 | $0.55 | ||
| Q4 24 | $0.74 | $0.46 | ||
| Q3 24 | $0.70 | $1.21 | ||
| Q2 24 | $1.32 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $107.4M | $618.7M |
| Total DebtLower is stronger | $5.0B | $9.0B |
| Stockholders' EquityBook value | $3.2B | $9.7B |
| Total Assets | $9.1B | $19.6B |
| Debt / EquityLower = less leverage | 1.53× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $107.4M | — | ||
| Q4 25 | $107.4M | $618.7M | ||
| Q3 25 | $111.3M | $938.9M | ||
| Q2 25 | $177.0M | $631.9M | ||
| Q1 25 | $109.2M | $1.1B | ||
| Q4 24 | $123.4M | $929.0M | ||
| Q3 24 | $97.0M | $950.1M | ||
| Q2 24 | $103.2M | $1.8B |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $4.5B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $9.7B | ||
| Q3 25 | $3.2B | $9.6B | ||
| Q2 25 | $3.2B | $9.5B | ||
| Q1 25 | $3.2B | $9.8B | ||
| Q4 24 | $3.2B | $10.3B | ||
| Q3 24 | $3.1B | $10.3B | ||
| Q2 24 | $3.0B | $9.8B |
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.1B | $19.6B | ||
| Q3 25 | $8.9B | $19.3B | ||
| Q2 25 | $8.6B | $18.3B | ||
| Q1 25 | $8.6B | $17.6B | ||
| Q4 24 | $8.5B | $18.2B | ||
| Q3 24 | $8.5B | $18.0B | ||
| Q2 24 | $8.4B | $17.7B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.53× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.42× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $622.4M | $827.1M | ||
| Q3 25 | $147.8M | $702.6M | ||
| Q2 25 | $150.7M | $364.0M | ||
| Q1 25 | $179.0M | $596.1M | ||
| Q4 24 | $574.6M | $742.5M | ||
| Q3 24 | $144.1M | $703.6M | ||
| Q2 24 | $169.7M | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | 4.80× | 3.86× | ||
| Q3 25 | 2.40× | 2.44× | ||
| Q2 25 | 0.97× | 12.06× | ||
| Q1 25 | 2.81× | 2.50× | ||
| Q4 24 | 8.77× | 3.57× | ||
| Q3 24 | 2.36× | 1.29× | ||
| Q2 24 | 1.52× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRT
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
